Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Biotech
With ph. 1 data, Aura has an eye on early-stage bladder cancer
Aura’s viruslike drug conjugate bel-sar and light activation completely eradicated the tumors of four out of five patients with low-grade disease.
Darren Incorvaia
Oct 17, 2024 4:05pm
J&J stops phase 3 bladder cancer trial after interim review flop
Oct 8, 2024 4:58am
enGene drops cystic fibrosis program to focus on bladder cancer
Jun 14, 2024 8:20am
CG sets new bar in bladder cancer, months after huge IPO
May 3, 2024 11:23am
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
Jan 3, 2024 8:25am
ImmunityBio inks $210M royalty deal to get cancer drug to market
Jan 2, 2024 7:41am
